Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
life sciences
national blog main
ucb
4
×
biotech
boston blog main
boston top stories
clinical trials
national
san francisco blog main
san francisco top stories
alexion pharmaceuticals
amgen
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
medicare
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
89bio
abaloparatide
abbvie
adrian krainer
What
drug
europe
pharma
administration
alternative
alzheimer’s
amgen
amgen’s
angry
annual
anti
approval
assessed
attention
autoimmune
benefited
bio
biotech
candidate
carries
communities
conference
deal
despite
developed
disease
esmo
european
expensive
fear
germany
heart
hosted
industry
investment
lead
losing
marketing
medicine
medicines
Language
unset
Current search:
ucb
×
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
